Kymera Investor Day Presentation Deck
Kymera Can Develop Degraders with Predictable Drug-Like Properties
Pre-clinical Optimization of Degraders Leads to High Oral Bioavailability Across Pre-clinical Species
Ternary Complex Modeling (TCM)
Harnessing the power of cloud
computing and Al to evaluate millions
of TCM models
DMPK Properties
HLM / RLM (uL/min/mg)
P. (10-6 cm/s) / Efflux Ratio
app
Rat Cl (mL/min/kg) / Vdss / F%
Dog Cl (mL/min/kg) / Vdss / F%
Monkey Cl (mL/min/kg) / Vdss / F%
KYMERA ©2021 KYMERA THERAPEUTICS, INC.
${
Molecular Chameleonicity
Accurately capturing the chameleonic
nature of degraders to predict
ADME/PK profile
Degrader 1
317 / 193
ND / ND
ND
ND
ND
Degrader 2
74 / 22
6.0 / 1.3
35/9/8
69 / 19 / 9
129 / 16 / 1
KYMERA R&D DAY - December 16th, 2021
Al-driven Insights
Leveraging deep-learning to
derive design insights from in
silico and in vitro data
Degrader 3
<12/<12
14/21
19/7/14
15/11/58
33 / 16 / 45
Degrader 4
<12 / <12
4.3 / 2.0
7/3/18
6/4/60
9/6/62
PAGE 94View entire presentation